Phosphatase inhibitor, sodium stibogluconate, in combination with interferon (IFN) alpha 2b: Phase I trials to identify pharmacodynamic and clinical effects

Oncotarget

Volumn 2, Issue 12, 2011, Pages 1155-1164

  Yi, Taolin ^a,b   Elson, Paul ^a   Mitsuhashi, Masato ^c   Jacobs, Barbara ^a   Hollovary, Emese ^a   Budd, G Thomas ^a   Spiro, Timothy ^a   Triozzi, Pierre ^a   Borden, Ernest C ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c Hitachi Chemical Research Center   (United States)

Author keywords

Cancer; Ifn 2 ; Phase I trial; Phosphatase inhibitor; SSG

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIMONY GLUCONATE; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; ENZYME INHIBITOR; PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; RECOMBINANT PROTEIN; VINBLASTINE;

ADULT; AGED; ARTICLE; BLOOD; BREAST TUMOR; CLINICAL TRIAL; COLORECTAL TUMOR; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MALE; MELANOMA; METHODOLOGY; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; SARCOMA;

ADULT; AGED; ANTIMONY SODIUM GLUCONATE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CISPLATIN; COLORECTAL NEOPLASMS; DACARBAZINE; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INTERFERON-ALPHA; MALE; MELANOMA; MIDDLE AGED; PHOSPHORIC MONOESTER HYDROLASES; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6; RECOMBINANT PROTEINS; SARCOMA; VINBLASTINE;

EID: 84861346452     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.563     Document Type: Article

References (55)

1. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol. 2006;7:833-46.
2. Lorenz U. SHP-1 and SHP-2 in T cells: two phosphatases functioning at many levels. Immunological reviews. 2009;228:342-59.
3. Neel BG, Gu H, Pao L. The 'Shp'ing news: SH2 domaincontaining tyrosine phosphatases in cell signaling. Trends Biochem Sci. 2003;28:284-93.
4. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 proteintyrosine-phosphatase deficiency. Trends Biotechnol. 1997;15:302-7.
5. Yi T, Lindner DJ. The role and target potential of protein tyrosine phosphatases in cancer. Current Oncology Reports. 2008;10:114-21.
6. Zhang J, Somani AK, Siminovitch KA. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol. 1999;12:361-78.
7. Croker BA, Lawson BR, Rutschmann S, Berger M, Eidenschenk C, Blasius AL, et al. Inflammation and autoimmunity caused by a SHP1 mutation depend on IL-1, MyD88, and a microbial trigger. Proceedings of the National Academy of Sciences of the United States of America. 2008;105:15028-33.
8. Fowler CC, Pao LI, Blattman JN, Greenberg PD. SHP-1 in T cells limits the production of CD8 effector cells without impacting the formation of long-lived central memory cells. Journal of immunology. 2010;185:3256-67.
9. Shultz LD, Schweitzer PA, Rajan TV, Yi T, Ihle JN, Matthews RJ, et al. Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell. 1993;73:1445-54.
10. Tsui HW, Siminovitch KA, de Souza L, Tsui FW. Motheaten and viable motheaten mice have mutations in the haematopoietic cell phosphatase gene. Nature Genetics. 1993;4:124-9.
11. Berman JD. Chemotherapy for leishmaniasis: biochemical mechanisms, clinical efficacy, and future strategies. Rev Infect Dis. 1988;10:560-86.
12. Pathak MK, Yi T. Sodium stibogluconate is a potent inhibitor of protein tyrosine phosphatases and augments cytokine responses in hemopoietic cell lines. J Immunol. 2001;167:3391-7.
13. Pathak MK, Hu X, Yi T. Effects of sodium stibogluconate on differentiation and proliferation of human myeloid leukemia cell lines in vitro. Leukemia. 2002;16:2285-91.
14. Yi T, Pathak MK, Lindner DJ, Ketterer ME, Farver C, Borden EC. Anticancer activity of sodium stibogluconate in synergy with IFNs. J Immunol. 2002;169:5978-85.
15. Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med Hyg. 1992;46:296-306.
16. Morphy R. Selectively nonselective kinase inhibition: striking the right balance. J Med Chem. 2010;53:1413-37.
17. David M, Chen HE, Goelz S, Larner AC, Neel BG. Differential regulation of the alpha/beta interferonstimulated Jak/Stat pathway by the SH2 domaincontaining tyrosine phosphatase SHPTP1. Mol Cell Biol. 1995;15:7050-8.
18. You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol. 1999;19:2416-24.
19. Myers MP, Andersen JN, Cheng A, Tremblay ML, Horvath CM, Parisien JP, et al. TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem. 2001;276:47771-4.
20. Darnell JE, Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res. 1998;18:549-54.
21. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
22. Binstadt BA, Billadeau DD, Jevremovic D, Williams BL, Fang N, Yi T, et al. SLP-76 is a direct substrate of SHP-1 recruited to killer cell inhibitory receptors. J Biol Chem. 1998;273:27518-23.
23. Chiang GG, Sefton BM. Specific dephosphorylation of the Lck tyrosine protein kinase at Tyr-394 by the SHP-1 proteintyrosine phosphatase. J Biol Chem. 2001;276:23173-8.
24. Plas DR, Johnson R, Pingel JT, Matthews RJ, Dalton M, Roy G, et al. Direct regulation of ZAP-70 by SHP-1 in T cell antigen receptor signaling. Science. 1996;272:1173-6.
25. Stefanova I, Hemmer B, Vergelli M, Martin R, Biddison WE, Germain RN. TCR ligand discrimination is enforced by competing ERK positive and SHP-1 negative feedback pathways. Nature immunology. 2003;4:248-54.
26. Wu TR, Hong YK, Wang XD, Ling MY, Dragoi AM, Chung AS, et al. SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei. The Journal of biological chemistry. 2002;277:47572-80.
27. Kemp M, Kurtzhals JA, Kharazmi A, Theander TG. Interferon-gamma and interleukin-4 in human Leishmania donovani infections. Immunol Cell Biol. 1993;71 (Pt 6):583-7.
28. Murray HW, Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect Immun. 2000;68:288-93.
29. Alexander J, Carter KC, Al-Fasi N, Satoskar A, Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol. 2000;30:2935-43.
30. Berman JD, Wyler DJ. An in vitro model for investigation of chemotherapeutic agents in leishmaniasis. J Infect Dis. 1980;142:83-6.
31. Nandan D, Yi T, Lopez M, Lai C, Reiner NE. Leishmania EF-1alpha activates the Src homology 2 domain containing tyrosine phosphatase SHP-1 leading to macrophage deactivation. J Biol Chem. 2002;277:50190-7.
32. Matin SF, Rackley RR, Sadhukhan PC, Kim MS, Novick AC, Bandyopadhyay SK. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 2001;61:2261-6.
33. Naing A, Reuben JM, Camacho LH, Gao H, Lee BN, Cohen EN, et al. Phase I Dose Escalation Study of Sodium Stibogluconate (SSG), a Protein Tyrosine Phosphatase Inhibitor, Combined with Interferon Alpha for Patients with Solid Tumors. Journal of Cancer. 2011;2:81-9.
34. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nature reviews Drug discovery. 2007;6:975-90.
35. Darnell J, Jr. Studies of IFN-induced transcriptional activation uncover the Jak-Stat pathway. J Interferon Cytokine Res. 1998;18:549-54.
36. Borden EC, Williams BR. Interferon-stimulated genes and their protein products: what and how? Journal of interferon & cytokine research: the official journal of the International Society for Interferon and Cytokine Research. 2011;31:1-4.
37. Pani G, Fischer KD, Mlinaric-Rascan I, Siminovitch KA. Signaling capacity of the T cell antigen receptor is negatively regulated by the PTP1C tyrosine phosphatase. J Exp Med. 1996;184:839-52.
38. Burshtyn DN, Scharenberg AM, Wagtmann N, Rajagopalan S, Berrada K, Yi T, et al. Recruitment of tyrosine phosphatase HCP by the killer cell inhibitor receptor. Immunity. 1996;4:77-85.
39. Nakayama K, Takahashi K, Shultz LD, Miyakawa K, Tomita K. Abnormal development and differentiation of macrophages and dendritic cells in viable motheaten mutant mice deficient in haematopoietic cell phosphatase. Int J Exp Pathol. 1997;78:245-57.
40. Feinerman O, Veiga J, Dorfman JR, Germain RN, Altan-Bonnet G. Variability and robustness in T cell activation from regulated heterogeneity in protein levels. Science. 2008;321:1081-4.
41. Johnson KG, LeRoy FG, Borysiewicz LK, Matthews RJ. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J Immunol. 1999;162:3802-13.
42. Carter JD, Neel BG, Lorenz U. The tyrosine phosphatase SHP-1 influences thymocyte selection by setting TCR signaling thresholds. Int Immunol. 1999;11:1999-2014.
43. Coggeshall KM, Nakamura K, Phee H. How do inhibitory phosphatases work? Mol Immunol. 2002;39:521-9.
44. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev. 2006;214:73-91.
45. Fan K, Zhou M, Pathak MK, Lindner DJ, Altuntas CZ, Tuohy VK, et al. Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumorinfiltrating macrophages. J Immunol. 2005;175:7003-8.
46. Wang SF, Fouquet S, Chapon M, Salmon H, Regnier F, Labroquere K, et al. Early T cell signalling is reversibly altered in PD-1+ T lymphocytes infiltrating human tumors. PloS one. 2011;6:e17621.
47. Monu N, Frey AB. Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells. Cancer research. 2007;67:11447-54.
48. Peng C, Chen Y, Li D, Li S. Role of Pten in leukemia stem cells. Oncotarget. 2010;1:156-60.
49. Lazo JS, Wipf P. Small molecule regulation of phosphatase-dependent cell signaling pathways. Oncol Res. 2003;13:347-52.
50. Zhang ZY. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu Rev Pharmacol Toxicol. 2002;42:209-34.
51. Zhuang Z, Lu J, Lonser R, Kovach JS. Enhancement of cancer chemotherapy by simultaneously altering cell cycle progression and DNA-damage defenses through global modification of the serine/threonine phospho-proteome. Cell Cycle. 2009;8:3303-6.
52. Kundu S, Fan K, Cao M, Lindner DJ, Tuthill R, Liu L, et al. Tyrosine phosphatase inhibitor-3 sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. Molecular cancer therapeutics. 2010;9:2287-96.
53. Kundu S, Fan K, Cao M, Lindner DJ, Zhao ZJ, Borden E, et al. Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents. Journal of immunology. 2010;184:6529-36.
54. Mitsuhashi M. Ex vivo simulation of leukocyte function: stimulation of specific subset of leukocytes in whole blood followed by the measurement of function-associated mRNAs. Journal of immunological methods. 2010;363:95-100.
55. Berman JD, Grogl M. Leishmania mexicana: chemistry and biochemistry of sodium stibogluconate (Pentostam). Experimental parasitology. 1988;67:96-103.